Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
immunicell
- Development stage
- Discontinued
- Lead developer
- TC BioPharm
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ImmuniCell is an autologous cell therapy developed as an anti-cancer immunotherapy. The treatment involves the expansion of a patient’s own gamma delta T cells over several weeks, which are then re-infused to target and attack cancer cells. This approach leverages the innate immune properties of gamma delta T cells, aiming to provide a broad-spectrum anti-tumor effect across various cancer types. The technology was initially developed and commercialized by Medinet in Japan, where it has been used to treat numerous cancer patients. TC Biopharm has further developed and trialed this therapy in Europe for cancers such as melanoma, kidney cancer, and lung cancer[9].
- Brand names
- ImmuniCell
- Other names
- ImmuniCell
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on immunicell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on immunicell.